Anjelli Wignakumar Profile
Anjelli Wignakumar

@AWignakumar

Followers
79
Following
513
Media
32
Statuses
244

Clinical Research Fellow at @CleveClinicFL

Florida, USA
Joined November 2020
Don't wanna be here? Send us removal request.
@dr_samehhany81
Sameh Emile, MD, FACS
7 days
New pub: Sociodemographic Determinants Associated with the Receipt of Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Population-Based Study from the SEER Registry @SWexner @nirhoresh @ZGaroufalia @BoutrosMarylise @AWignakumar https://t.co/eUp9n2mNWc
Tweet card summary image
link.springer.com
Journal of Gastrointestinal Cancer - Approximately 35% of patients do not receive adjuvant chemotherapy (AC) after surgery for stage III colorectal cancer (CRC). We aimed to investigate the...
0
7
11
@dr_samehhany81
Sameh Emile, MD, FACS
12 days
New pub: Advanced T stage and Nodal Disease are Independently Associated with Worse Cancer-Specific Survival in Stage IV Colorectal Cancer: A SEER-Based Survival Analysis @ejsotweets @SWexner @nirhoresh @BoutrosMarylise @AWignakumar https://t.co/LRQwIWohso
Tweet card summary image
ejso.com
Stage IV colorectal cancer (CRC) is associated with 5-year survival <15%. We aimed to investigate the association between T and N stages of stage IV CRC.
0
3
3
@SWexner
Steven D Wexner MD, PhD
28 days
Superb cutting edge information shared at LESM πŸ‡²πŸ‡Ή by @laptan1
2
1
6
@dr_samehhany81
Sameh Emile, MD, FACS
1 month
Splenic flexure cancers account for β‰ˆ 5% of colorectal cancer & are usually challenging to treat. Our scoping review explored variations in surgical approach, extent of resection & lymphadenectomy in splenic flexure tumors @SWexner @ZGaroufalia @nirhoresh
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
Surgical treatment of splenic flexure tumors remains controversial due to the lack of high-quality prospective data. No single approach can currently be recommended for all cases. Until randomized...
0
7
14
@TomVargheseJr
Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE πŸ‡ΊπŸ‡Έ
1 month
β€œTrue heroism is remarkably sober, very undramatic. It is not the urge to surpass all others at whatever cost, but the urge to serve others at whatever cost.” - Arthur Ashe Bravery, sacrifice and service. May we honor those who serve this day and all through our actions. 🫑
0
5
14
@DouradoJMD
Justin Dourado, MD
1 month
Surgical Management of Small Bowel Neuroendocrine Neoplasms in Crohn's https://t.co/kyWqZUd2HQ @SWexner @AWignakumar
0
1
2
@BoutrosMarylise
Marylise Boutros
1 month
Most sincere and huge congratulations @SWexner πŸŽ‰ ! @MedStarHealth @Georgetown has gained a leader, visionary and mentor like no other! You will build and grow all around you. I can’t wait to celebrate your next successes. Your legacy continues!
@SWexner
Steven D Wexner MD, PhD
2 months
Excited, energized, and eager to start my new role on November 1, 2025 as inaugural Physician Executive Director and System Chief for Colorectal Surgery and Vice Chair for Professional Development for the Department of Surgery @MedStarHealth @Georgetown @AmCollSurgeons
1
6
37
@SWexner
Steven D Wexner MD, PhD
2 months
Excited, energized, and eager to start my new role on November 1, 2025 as inaugural Physician Executive Director and System Chief for Colorectal Surgery and Vice Chair for Professional Development for the Department of Surgery @MedStarHealth @Georgetown @AmCollSurgeons
57
38
262
@SWexner
Steven D Wexner MD, PhD
2 months
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis: Therapeutic advancement or clinical controversy? An institutional review - @SurgJournal https://t.co/y26iYv4Kzc
1
12
22
@SWexner
Steven D Wexner MD, PhD
2 months
An umbrella review of systematic reviews on the diagnostic and prognos... https://t.co/2sq7fhlrer new publication @dr_samehhany81 @AWignakumar @nirhoresh @ZGaroufalia
0
6
9
@AWignakumar
Anjelli Wignakumar
2 months
Thank you so much, Dr Varghese! It means a tremendous amount! 😊
@TomVargheseJr
Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE πŸ‡ΊπŸ‡Έ
2 months
@AWignakumar @dr_samehhany81 @SWexner @BoutrosMarylise @acsJACS Congrats! Thanks to you and your team for submitting the amazing work to @acsJACS πŸ˜ŠπŸ™ŒπŸΎ
0
3
3
@AWignakumar
Anjelli Wignakumar
2 months
Thank you, Dr Wexner!
@SWexner
Steven D Wexner MD, PhD
2 months
Congratulations @AWignakumar very proud of you
0
0
0
@AWignakumar
Anjelli Wignakumar
2 months
My second first author paper in JACS! Receiving the acceptance email at #ACSCC25 in Chicago was a full circle moment. As always, the unwavering support from @dr_samehhany81 and @SWexner. Thank you @BoutrosMarylise and my co-authors! @acsJACS
@dr_samehhany81
Sameh Emile, MD, FACS
2 months
New pub: Development of a Predictive Calculator for the Need for Abdominoperineal Resection after Chemoradiation Therapy in Anal Squamous Cell Carcinoma @acsJACS @SWexner @AWignakumar @BoutrosMarylise https://t.co/uJwWqQL0Va
2
4
8
@AWignakumar
Anjelli Wignakumar
2 months
Very exciting new publication on the use of ctDNA in colorectal cancer.
@dr_samehhany81
Sameh Emile, MD, FACS
2 months
New pub: An umbrella review of systematic reviews on the diagnostic and prognostic utility of circulating tumor DNA and MicroRNA in colorectal cancer @SWexner @nirhoresh @AWignakumar @ZGaroufalia https://t.co/7pAnIfqTzW
0
1
1
@AWignakumar
Anjelli Wignakumar
2 months
New publication!
@SWexner
Steven D Wexner MD, PhD
2 months
An umbrella review of systematic reviews on the diagnostic and prognos... https://t.co/2sq7fhlrer new publication @dr_samehhany81 @ZGaroufalia @AWignakumar
0
0
0
@SWexner
Steven D Wexner MD, PhD
2 months
An umbrella review of systematic reviews on the diagnostic and prognos... https://t.co/2sq7fhlrer new publication @dr_samehhany81 @ZGaroufalia @AWignakumar
0
4
9
@AWignakumar
Anjelli Wignakumar
2 months
Very exciting new publication!
@dr_samehhany81
Sameh Emile, MD, FACS
2 months
New pub: Target trial on the outcomes of laparoscopic compared to robotic-assisted proctectomy in stage II–III rectal cancer @SWexner @nirhoresh @MarcusOosenbrug @salama_ebram @AWignakumar @VictorSTRASSMA2 https://t.co/iRZoDjFWQ3
0
1
0